Effect of N-Acetylcysteine on Autologous Fat Graft Survival

Sponsor
Michael Bezuhly (Other)
Overall Status
Unknown status
CT.gov ID
NCT02788292
Collaborator
(none)
14
2
23

Study Details

Study Description

Brief Summary

A single-centre triple-blind study looking at the addition of NAC to tumescent solution for liposuction and fat grafting in healthy patient volunteers already undergoing bilateral breast reduction. Three-dimensional reconstructions and volumetric analysis will be performed based on CT scans at 0, 1 and 3 months and then histological analysis will be performed after fat graft explantation at 3 months to determine fat graft vascularity and quality.

Condition or Disease Intervention/Treatment Phase
Phase 4

Detailed Description

Autologous fat grafting is an increasingly popular technique for soft tissue reconstruction; however, the surgical technique is limited by inconsistent graft take, undercorrection, and requirement for repeat procedures. The authors previously examined whether a widely available, clinically safe anti-oxidant, N-acetylcysteine (NAC), could improve adipose-derived stem cell survival and subsequent graft take when added to tumescent solution at the time of fat harvest in mice. The addition of NAC to tumescent fluid during fat harvest in mice protects ADSCs against oxidative stress, increases their survival and proliferation, and inhibits their early differentiation into mature adipocytes in vitro. In an in vivo model, NAC treatment at the time of harvest improved survival and quality of autologous fat grafts. These observations provide proof-of-principle for the use of NAC in the clinical setting to optimize fat graft yields.

Hypothesis: The addition of NAC to the tumescent solution used in fat grafting will improve fat graft survival in humans to potentially decrease the amount of re-operations and undercorrection that occurs.

Plan: The study will be conducted as a single-centre, randomized, triple-blind placebo-controlled trial to be performed at the QEII Health Sciences Centre, Halifax, Nova Scotia. Subjects will be chosen as healthy female patients already presenting to the operating room for elective breast reduction surgery. These patients will be enrolled and booked for surgery as they present to clinic and will not be expedited in receiving their elective surgery if enrolled in the study. Each subject will serve as her own control. The hypothesis will be tested by performing lipoaspiration of the thigh/hip region of healthy patients after the addition of tumescent solution with or without NAC. Approximately 10 millilitres of the fat graft will be injected into each pre-tibial area depending on the randomization allocation, as described by Kolle et al. (1) The volume of fat graft will be measured at 0, 1 and 3 months using computed tomographic (CT) scans according to institutional standards. The CT images will be exported into Materialise Interactive Medical Image Control System (MIMICS) and volumetric three-dimensional reconstructions will be made to measure the size and volume of the grafts at each of the time points. The grafts will then be explanted at 3 months and weighed. The histologic appearance, graded on the amount of inflammation, cysts/vacuoles, integrity and vascularity with CD31 staining will be assessed. The results will be compared using two-tailed t-tests. Statistical significance will be set at p<0.05.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
14 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
Effect of N-Acetylcysteine on Autologous Fat Graft Survival
Study Start Date :
Jul 1, 2016
Anticipated Primary Completion Date :
Dec 1, 2017
Anticipated Study Completion Date :
Jun 1, 2018

Arms and Interventions

Arm Intervention/Treatment
Experimental: Acetylcysteine (NAC)

NAC added to tumescent solution for liposuction and eventual fat grafting.

Drug: Acetylcysteine
See arm description
Other Names:
  • N-acetylcysteine
  • No Intervention: Control

    Just tumescent solution for liposuction and fat grafting.

    Outcome Measures

    Primary Outcome Measures

    1. Change in fat graft volume over time [0, 1 and 3 months]

      Based on CT scans of fat grafts and three-dimensional reconstructions/volumetric analysis

    Secondary Outcome Measures

    1. Weight of fat graft [3 months]

      Fat grafts will be explanted and weighed at 3 months.

    2. Fat graft vascularity [3 months]

      Vascularity of fat graft with CD31 staining.

    3. Fat graft quality [3 months]

      Quality of fat graft through histological analysis of cysts/vacuoles/intact fat cells/fibrosis and also through adipocyte slide coverage analysis.

    4. Adverse effects or complications [1 year]

      Collecting data regarding any adverse complications of the fat grafting procedure and subsequent recovery.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 45 Years
    Sexes Eligible for Study:
    Female
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:
    1. Women

    2. Desire and surgical indication for liposuction of the thigh/hip region for women already undergoing elective breast reduction surgery

    3. Age 18-45 years

    4. BMI of 20-30

    5. ASA Class I

    Exclusion Criteria:
    1. Known chronic illnesses: Diabetes, HIV, renal/liver failure, metabolic disease, history of cancer or family pre-disposition of cancer, peripheral vascular disease, illness that would preclude a general anaesthetic

    2. Pregnancy or planned pregnancy within 1 year

    3. Contraindications to CT

    4. Previous hip/thigh surgery or injury

    5. Previous lower leg surgery/injury

    6. Smoker

    7. Breastfeeding

    8. Other disease according to investigator's judgment

    Contacts and Locations

    Locations

    No locations specified.

    Sponsors and Collaborators

    • Michael Bezuhly

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Michael Bezuhly, General Surgeon, Nova Scotia Health Authority
    ClinicalTrials.gov Identifier:
    NCT02788292
    Other Study ID Numbers:
    • NSHA-RS/2016-2961
    First Posted:
    Jun 2, 2016
    Last Update Posted:
    Jun 2, 2016
    Last Verified:
    May 1, 2016
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Keywords provided by Michael Bezuhly, General Surgeon, Nova Scotia Health Authority
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Jun 2, 2016